Thursday, 07. May 2020

PARI Nebulizer Used in New Study with Pulmotect’s Inhaled PUL-042 for COVID-19

Midlothian, Virginia; May 7, 2020 –This week, the first patients are enrolling in two phase 2 clinical trials for COVID-19 using Pulmotect’s PUL-042,...
Wednesday, 03. April 2019

Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome

– Phase 3 BOSTON clinical studies will evaluate Liposomal Cyclosporine A for Inhalation (L-CsA-i), the first potential therapy for Bronchiolitis...
Friday, 06. April 2018

Sunovion Announces Lonhala™ Magnair™ (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD

LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) available for the treatment of COPD in the U.S.
Monday, 25. September 2017

ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis


Key updates

  • QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment.
  • A...


Wednesday, 02. November 2016

Sunovion Announces FDA Filing Acceptance of New Drug Application for Sun-101/eFlow® for the Treatment of Patients with Chronic Obstuctive Pulmonary Disease (COPD)

- Sun-101/eflow® (glycopyrrolate) NDA is currently under review; if approved, it would represent the first available nebulized long-acting muscarinic...